FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2540652203> ?p ?o ?g. }

• W2540652203 abstract "e22169 Background: Topoisomerase IIα protein(topo II) is the molecular target of topo II inhibitors such as anthracyclines and Microtubule-Associated Protein(MAP)-tau protein is associated with taxane sensitivity. Anthracyclins and taxanes are major cytotoxic agents of breast cancer in the adjuvant setting. The aim of this study was to evaluate the predictive and prognostic functions of MAP-tau and topo II in early breast cancers. Methods: Representative breast tumor sections were constructed from paraffin embedded specimens from 78 node positive breast cancer patients. MAP-tau and topo II protein were assessed by immunochemistry using antibody clone 4F1(Affinity BioReagents,USA) and clone Ki-S1 antibody(Dakocytomation,USA). MAP-tau staining of tumor cells was semiquantatively scored as 0, 1+, 2+, 3+ and cases with 0 or 1+ staining intensity were considered MAP-tau negative. Topo II protein over- expression was defined as the detection of nuclear staining in more than median value of evaluated cells. Results: Thirty- four cases (43.6%) of 78 samples showed topo II overexpression and 35 cases(44.9%) showed MAP-tau overexpression in node positive breast cancers. HER2 overexpression was noted in 28 samples (35.9%) and 56 cases (71.8%) were compatible with the luminal type. In 43 patients (55.1%), anthracyclin and taxane were used as adjuvant therapy and in this group, both MAP-tau and topo II overexpression showed lower disease-free survival (DFS) than the others, but statistically not significant. In luminal type, MAP-tau overexpression was poor prognostic factor on DFS in Cox regression.(HR 5.644, 95% CI 1.14–28.07, p=0.034) Conclusions: Topo II overexpression and MAP-tau overexpression in node positive breast cancers were not significant predictive factors for anthracyclin and taxane therapies. As several investigators reported, MAP-tau is associated endocrine therapy sensitivity in patients without chemotherapy, but higher MAP-tau in luminal type was a strong poor prognostic factor in patients who were given chemotherapy and hormonal therapy. No significant financial relationships to disclose." @default.
• W2540652203 created "2016-11-04" @default.
• W2540652203 creator A5006972618 @default.
• W2540652203 creator A5008618735 @default.
• W2540652203 creator A5028408362 @default.
• W2540652203 creator A5036775045 @default.
• W2540652203 creator A5051994169 @default.
• W2540652203 creator A5060052745 @default.
• W2540652203 creator A5071371580 @default.
• W2540652203 creator A5079017028 @default.
• W2540652203 creator A5088383868 @default.
• W2540652203 date "2009-05-20" @default.
• W2540652203 modified "2023-09-26" @default.
• W2540652203 title "Predictive and prognostic functions of microtubule-associated protein-tau and topoisomerase IIα protein in early breast cancer" @default.
• W2540652203 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e22169" @default.
• W2540652203 hasPublicationYear "2009" @default.
• W2540652203 type Work @default.
• W2540652203 sameAs 2540652203 @default.
• W2540652203 citedByCount "0" @default.
• W2540652203 crossrefType "journal-article" @default.
• W2540652203 hasAuthorship W2540652203A5006972618 @default.
• W2540652203 hasAuthorship W2540652203A5008618735 @default.
• W2540652203 hasAuthorship W2540652203A5028408362 @default.
• W2540652203 hasAuthorship W2540652203A5036775045 @default.
• W2540652203 hasAuthorship W2540652203A5051994169 @default.
• W2540652203 hasAuthorship W2540652203A5060052745 @default.
• W2540652203 hasAuthorship W2540652203A5071371580 @default.
• W2540652203 hasAuthorship W2540652203A5079017028 @default.
• W2540652203 hasAuthorship W2540652203A5088383868 @default.
• W2540652203 hasConcept C121608353 @default.
• W2540652203 hasConcept C126322002 @default.
• W2540652203 hasConcept C142724271 @default.
• W2540652203 hasConcept C143998085 @default.
• W2540652203 hasConcept C147897179 @default.
• W2540652203 hasConcept C153911025 @default.
• W2540652203 hasConcept C159654299 @default.
• W2540652203 hasConcept C181199279 @default.
• W2540652203 hasConcept C203014093 @default.
• W2540652203 hasConcept C204232928 @default.
• W2540652203 hasConcept C2777511904 @default.
• W2540652203 hasConcept C2778670691 @default.
• W2540652203 hasConcept C2779134260 @default.
• W2540652203 hasConcept C2780659158 @default.
• W2540652203 hasConcept C502032728 @default.
• W2540652203 hasConcept C502942594 @default.
• W2540652203 hasConcept C530470458 @default.
• W2540652203 hasConcept C552990157 @default.
• W2540652203 hasConcept C55493867 @default.
• W2540652203 hasConcept C71924100 @default.
• W2540652203 hasConcept C74864618 @default.
• W2540652203 hasConcept C81089528 @default.
• W2540652203 hasConcept C86803240 @default.
• W2540652203 hasConceptScore W2540652203C121608353 @default.
• W2540652203 hasConceptScore W2540652203C126322002 @default.
• W2540652203 hasConceptScore W2540652203C142724271 @default.
• W2540652203 hasConceptScore W2540652203C143998085 @default.
• W2540652203 hasConceptScore W2540652203C147897179 @default.
• W2540652203 hasConceptScore W2540652203C153911025 @default.
• W2540652203 hasConceptScore W2540652203C159654299 @default.
• W2540652203 hasConceptScore W2540652203C181199279 @default.
• W2540652203 hasConceptScore W2540652203C203014093 @default.
• W2540652203 hasConceptScore W2540652203C204232928 @default.
• W2540652203 hasConceptScore W2540652203C2777511904 @default.
• W2540652203 hasConceptScore W2540652203C2778670691 @default.
• W2540652203 hasConceptScore W2540652203C2779134260 @default.
• W2540652203 hasConceptScore W2540652203C2780659158 @default.
• W2540652203 hasConceptScore W2540652203C502032728 @default.
• W2540652203 hasConceptScore W2540652203C502942594 @default.
• W2540652203 hasConceptScore W2540652203C530470458 @default.
• W2540652203 hasConceptScore W2540652203C552990157 @default.
• W2540652203 hasConceptScore W2540652203C55493867 @default.
• W2540652203 hasConceptScore W2540652203C71924100 @default.
• W2540652203 hasConceptScore W2540652203C74864618 @default.
• W2540652203 hasConceptScore W2540652203C81089528 @default.
• W2540652203 hasConceptScore W2540652203C86803240 @default.
• W2540652203 hasLocation W25406522031 @default.
• W2540652203 hasOpenAccess W2540652203 @default.
• W2540652203 hasPrimaryLocation W25406522031 @default.
• W2540652203 hasRelatedWork W1775406873 @default.
• W2540652203 hasRelatedWork W2018823546 @default.
• W2540652203 hasRelatedWork W2054935282 @default.
• W2540652203 hasRelatedWork W2066000041 @default.
• W2540652203 hasRelatedWork W2130926505 @default.
• W2540652203 hasRelatedWork W2143860386 @default.
• W2540652203 hasRelatedWork W2171435729 @default.
• W2540652203 hasRelatedWork W2243613448 @default.
• W2540652203 hasRelatedWork W2285230598 @default.
• W2540652203 hasRelatedWork W2316506771 @default.
• W2540652203 hasRelatedWork W2319907632 @default.
• W2540652203 hasRelatedWork W2351956583 @default.
• W2540652203 hasRelatedWork W2408802367 @default.
• W2540652203 hasRelatedWork W2410645456 @default.
• W2540652203 hasRelatedWork W2588145826 @default.
• W2540652203 hasRelatedWork W2604225413 @default.
• W2540652203 hasRelatedWork W2943874168 @default.
• W2540652203 hasRelatedWork W2981414353 @default.
• W2540652203 hasRelatedWork W3182248420 @default.
• W2540652203 hasRelatedWork W98707964 @default.
• W2540652203 isParatext "false" @default.
• W2540652203 isRetracted "false" @default.

• next